Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: Tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages
- 1 November 1992
- journal article
- other
- Published by Elsevier in Immunobiology
- Vol. 186 (3-4) , 214-229
- https://doi.org/10.1016/s0171-2985(11)80251-2
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Interleukin 2‐dependent activation of tumor‐specific cytotoxic T lymphocytes in vivoEuropean Journal of Immunology, 1991
- Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytesCell, 1989
- Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia.The Journal of Experimental Medicine, 1989
- Characterization of recombinant glycosylated human interleukin 2 produced by a recombinant plasmid transformed CHO cell lineFEBS Letters, 1987
- Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection.The Journal of Experimental Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2Science, 1984
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- A rapid method for the isolation of functional thymus‐derived murine lymphocytesEuropean Journal of Immunology, 1973